使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day and thank you for standing by. Welcome to the Telix full year 2025 results and investor webcast. (Operator Instructions) Please be advised that today's conference is being recorded.
大家好,感謝您稍候。歡迎收看 Telix 2025 全年業績與投資人網路直播。(接線員指示) 請注意,今天的會議將被錄音。
I will now like to hand the conference over to your speaker today, Kyahn Williamson, SVP of Investor Relations and Corporate Communications. Please go ahead.
我現在要把會議交給今天的講者 Kyahn Williamson,投資人關係與企業傳播資深副總裁。請開始。
Kyahn Williamson - Senior Vice President, Investor Relations & Corporate Communications
Kyahn Williamson - Senior Vice President, Investor Relations & Corporate Communications
Thank you, and thank you to everybody for joining us on this call this morning, this evening where you are in the world. We launched our annual report full year results on the ASX about 30 minutes ago. We also have the slides on screen via webcast for you to see today. I'm just going to take you through a brief introduction, and some disclaimer statements before handing over, but if you just move to the slide 2.
謝謝,也感謝各位今天早上、或在您所在時區的今晚加入這通電話會議。我們大約在 30 分鐘前已在澳洲證交所(ASX)發布了全年業績的年度報告。我們也透過網路直播在螢幕上提供投影片供各位今天觀看。我將先做一個簡短的開場與若干免責聲明,之後再交棒;請先翻到第 2 頁投影片。
Very pleased to have on the call with us today, Chris Behrenbruch, our CEO and Managing Director; Darren Smith, our CFO; and Kevin Richardson, our CEO of the Precision Medicine business. I should also mention that we have Dr. David Cade, our Chief Medical Officer on the line for the Q&A session.
很高興今天與會的有:我們的執行長暨董事總經理 Chris Behrenbruch;財務長 Darren Smith;以及精準醫療事業部執行長 Kevin Richardson。我也要提到,我們的首席醫療長 David Cade 醫師將在線上參與問答環節。
We'll be running through today our strategy, financial results, and update on our Precision Medicine and Therapeutic achievement. If you can move to the next slide, please. I am required just to give you an excerpt from our forward-looking statement. So please note that on today's presentation includes forward booking statements, including within the meaning of the US Private Securities litigation Reform Act of 1995 that relates to among other things, anticipated future events, financial performance plans, strategies and business development.
今天我們將依序說明公司的策略、財務結果,以及精準醫療與治療領域的進展與成果。請翻到下一頁投影片。我需要先向各位宣讀一段前瞻性陳述的摘錄。請注意,今天的簡報包含前瞻性陳述,包括在 1995 年《美國私人證券訴訟改革法》(US Private Securities Litigation Reform Act of 1995)意義範圍內的陳述,內容涉及(但不限於)預期的未來事件、財務表現、計畫、策略與業務發展。
These forward and statements based on current information assumption of expectations of future events that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward booking statements.
這些前瞻性陳述係基於目前資訊、假設與對未來事件的預期,可能會變動,並涉及風險與不確定性,可能導致實際結果與前瞻性陳述所載內容出現重大差異。
These and others risks are described in our filings with the ASX and SEC, including on our half year and annual report. You of course should not rely on forward looking statements which are made earlier today's date, and the company claims no any obligation to update such statements. Please refer to this disclaimer slide in the presentation for further information.
這些以及其他風險已在我們向 ASX 與美國證券交易委員會(SEC)提交的文件中說明,包括半年度與年度報告。當然,您不應依賴截至今日較早時間所作的前瞻性陳述,且本公司不承擔更新該等陳述的任何義務。更多資訊請參閱簡報中的本免責聲明投影片。
With that, I'm very pleased to hand it over to Chris to kick off the call.
接下來,我很高興把時間交給 Chris 來開始今天的電話會議。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Thanks very much, Kyahn. I hope that my audio is nice and clear, and I certainly appreciate the introduction. Before Darren Smith, our Chief Financial Officer, goes into the numbers. I thought a bit of strategic framing would be useful for investors to understand where the company is heading, and of course our key accomplishments in 2025.
非常感謝你,Kyahn。希望我的音訊清楚,也非常感謝你的介紹。在我們的財務長 Darren Smith 進入數字細節之前,我想先從策略面做一些框架性的說明,讓投資人了解公司未來的方向,當然也包括我們在 2025 年的關鍵成果。
Next slide, please. Slide 5. Over the last 12 months, we've started to put the depth and execution around what has been a multi-year corporate development strategy. It's useful to think of Telix as a platform with these five major segments as illustrated on this slide.
請下一頁。第 5 頁投影片。在過去 12 個月,我們開始在一項多年期的企業發展策略上,建立更深的內涵並強化執行力。把 Telix 視為一個平台會很有幫助,如本頁投影片所示,平台包含五個主要區塊。
Moving from left to right, first stop of key focuses of therapeutics pipeline, which has grown significantly and now features three programs in pivotal studies, as well as several high potential earlier stage programs in rare diseases. I'm going to come back a little bit towards the end of the presentation on this topic.
由左至右,第一個重點是治療產品線(therapeutics pipeline),其規模已顯著成長,目前有三個計畫正處於關鍵性試驗(pivotal studies),同時也有數個在罕見疾病領域具高度潛力的早期計畫。我會在簡報接近尾聲時再回到這個主題。
Because of the explosive growth of activity in the radiopharma landscape. We have also pivoted to some extent to an internal innovation model alongside our business development activities. Clearly, when big pharma is willing to pay a billion dollars for an asset that has been in a few months, there's clearly an incentive to do in-house innovation. And so we now have a significant set of technical and clinical capabilities around fundamental R&D and discovery technologies.
由於放射性藥物(radiopharma)領域的活動呈爆炸性成長,我們也在一定程度上,除了業務開發活動之外,轉向採用內部創新模式。很明顯,當大型藥廠願意為一個僅開發了幾個月的資產支付 10 億美元時,內部創新就有很強的誘因。因此,我們現在在基礎研發與探索技術方面,已建立一套相當完整的技術與臨床能力。
In the middle of this vision, and the engine room of the commercial business today, is what we call the Precision Medicine business. This is far more than just an ATM machine that throws off a couple $100 million of cash each year. It's a strategic validation of the targets we develop our therapeutic drugs for. It is more robust and streamlined clinical trials because we can see where our drug goes. And it's an early opportunity to build deep relationships with the physician stakeholders that underpinned the future of the business.
在這個願景的核心、也是目前商業業務的引擎室,是我們所稱的精準醫療(Precision Medicine)事業。這遠不只是每年產生數億美元現金的「提款機」。它是我們為治療藥物所開發標的(targets)的策略性驗證。它也讓臨床試驗更穩健、更精簡,因為我們能看見藥物在體內的去向。同時,這也是及早與醫師利害關係人建立深度關係的機會,而這些關係將支撐公司未來的發展。
Fourth, one can obviously look at sales and the commercial team simply as SG&A. We view it as building a specialty sales organization that very few companies have, selling nuclear medicine is not selling a vial or a blister pack. It involves selling complex clinical workflows. And as our product portfolio expands, this is a strategic differentiator because it enables us to build depth with key referral physicians and drive preference towards our products.
第四點,有些人可能會把銷售與商業團隊單純視為銷售、一般及行政費用(SG&A)。我們則把它視為打造一個少數公司才具備的專科銷售組織;銷售核醫產品並不是賣一瓶藥或一板泡殼包裝。它涉及銷售複雜的臨床工作流程。隨著我們的產品組合擴大,這將成為策略性差異化優勢,因為它讓我們能與關鍵轉診醫師建立更深的連結,並推動醫師對我們產品的偏好。
There seems to be some background noise. If somebody needs to mute, they should do so. It's also fair to note that in the major markets, this is a significant financial investment that most of our competition, both present and emerging, cannot afford to undertake.
似乎有一些背景雜音。如果有人需要靜音,請將麥克風靜音。另外也必須指出,在主要市場中,這是一項重大的財務投資,我們多數競爭對手(無論是現有或新進者)都無力承擔。
Lastly, you can develop all the great ideas you want and convince people to buy them, but if you can't deliver them reliably every single day. You aren't going to succeed. And most industries, vertical integration is probably wasteful and doesn't offer much of a moat.
最後,你可以提出再多好點子、也能說服別人購買,但如果你無法每天都可靠地交付產品,你就不會成功。在多數產業中,垂直整合可能是浪費,且不太能形成護城河。
In radio pharmaceuticals, where you're dealing with products that have shelf life of hours to days at most. There's a huge amount of market share ownership dynamic, intellectual property, and customer differentiation in how you deliver. This is why we have invested over half a billion dollars in the last year to better control our destiny and pave the way for high-value therapeutic products. Next slide, please.
但在放射性藥物領域,你面對的是保存期限最多只有數小時到數天的產品。在「如何交付」這件事上,存在巨大的市占歸屬動態、智慧財產,以及客戶差異化。這也是為什麼我們在過去一年投資超過 5 億美元,以更好地掌控自身命運,並為高價值治療產品鋪路。請下一頁。
To do all these things, you need cash, and we have a very high growth business that made a step change this year, both through organic growth of our Precision Medicine business and through acquisition. We expect all of our revenue streams to continue to diversify and grow in 2026 and beyond, and Darren will cover this off on guidance later in this presentation. Kevin is also going to frame this in terms of the core growth of the Precision Medicine portfolio, which is extremely exciting. The key point is, we have a hypergrowth business and it generates the cash we need to aggressively expand further diversify our revenue and dominate the field.
要做到這些,你需要現金;而我們是一個高速成長的業務,今年出現了階躍式的提升,這既來自精準醫療事業的有機成長,也來自併購。我們預期所有收入來源在 2026 年及之後將持續多元化並成長;Darren 會在本簡報稍後的財測指引中說明。Kevin 也會從精準醫療產品組合的核心成長角度來做框架說明,這非常令人振奮。重點是:我們擁有一個超高速成長的業務,它能產生我們所需的現金,讓我們得以積極擴張、進一步分散收入來源,並在此領域取得主導地位。
Slide 7, please. This slide puts the whole strategy into perspective. As I've already said, to deliver on our bold vision for being the dominant player in radio pharma, we need a cash generative business. We have one, and we grew it significantly this year with revenues exceeding USD800 million or over AUD1.2 billion for anyone that prefers their greenback served with shrimp on barbie.
請看第 7 頁投影片。這張投影片讓整體策略更一目了然。如我先前所說,為了實現我們要成為放射性藥物領域主導者的宏大願景,我們需要一個能創造現金的業務。我們已經擁有,而且今年大幅成長,營收超過 8 億美元,或對於偏好以澳幣計價的人而言超過 12 億澳幣——也就是把美鈔配上「烤蝦」一起端上桌。
Our margins have remained extremely stable despite competition, and this excellent commercial performance enabled us to invest $0.5 billion into growing our product pipeline, funding the best commercial team in the industry and building our infrastructure and supply chain. Think about that. $0.5 billion grow the future value of the company from earnings without shareholder dilution. Telix is a very unique and valuable story.
儘管面臨競爭,我們的毛利率仍維持極為穩定;而這項卓越的商業表現,使我們得以投入 5 億美元來擴充產品線、資助業界最強的商業團隊,並建置我們的基礎設施與供應鏈。想想看:5 億美元,透過盈餘來提升公司未來價值,而不需要稀釋股東權益。Telix 是一個非常獨特且極具價值的故事。
Moving on to slide 8, please. Before I hand it over to Darren, I thought it would be useful to give you a condensed view of our priorities for 2026. I get a lot of feedback that Telix is complicated, but it really isn't. This year is about doing three things, and hopefully doing them better than we did last year.
接著請看第 8 張投影片。在我把時間交給 Darren 之前,我想先為各位簡要說明我們 2026 年的優先事項。我常收到回饋說 Telix 很複雜,但其實並不然。今年就是要做三件事,而且希望比去年做得更好。
One, we are going to continue to grow our core business around our approved products. We actually did get a new and innovative product approved by the FDA last year in Gozellix that also leverages the ARTMS isotope production acquisition. The launch of Gozellix has been successful, and is not only growing our ASP and market share, it will pave the way for many future products through both the RLS network and partner distributors, with Zircaix being the next prime example of this technology platform.
第一,我們將持續擴大以已核准產品為核心的核心業務。去年我們確實取得 FDA 核准一項全新且具創新性的產品 Gozellix,同時也運用我們收購 ARTMS 同位素生產所帶來的優勢。Gozellix 的上市推進相當成功,不僅提升我們的 ASP 與市占率,也將透過 RLS 網路與合作夥伴經銷商為未來多項產品鋪路,而 Zircaix 就是此技術平台的下一個重要例證。
Two, we have two new products to launch. Pixclara, which is known as Pixlumi in Europe, this is for glioblastoma, and Zircaix for renal cancer. We understand the disappointment that these did not get approved last year, but this is the price of being at the forefront of innovation and new technology areas.
第二,我們有兩項新產品要上市。Pixclara(在歐洲稱為 Pixlumi),用於膠質母細胞瘤,以及用於腎癌的 Zircaix。我們理解大家對於這些產品去年未獲核准感到失望,但這就是站在創新與新技術領域最前沿所需付出的代價。
While people are well aware, there's been a tumultuous period within the FDA itself. We also made certain we took valuable learnings from the experience. We have made extensive changes to the management team. We boosted our regulatory affairs capabilities.
大家也都很清楚,FDA 內部本身經歷了一段動盪期。我們也確保從這次經驗中汲取了寶貴的教訓。我們已對管理團隊進行大幅調整。並強化了我們的法規事務能力。
And these program are in good shape for resubmission and approval this year. They are highly anticipated products and will become significant revenue streams, and we have not taken our foot off the gas pedal in terms of market readiness for these products. We are preparing to launch, and I want to make that very clear.
而這些專案目前已具備良好條件,可在今年重新遞交並取得核准。它們是市場高度期待的產品,將成為重要的營收來源;在這些產品的市場就緒方面,我們也絲毫沒有鬆懈。我們正為上市做準備,我想把這點說得非常清楚。
Last of all, we have several, very high value clinical programs. This is not an exhaustive list. In fact, we have over 30 sponsored and collaborative studies running from early stage to pivotal trials. But these are the ones that are going to generate the greatest commercial and financial inflection points this year, and are the priority in terms of our resources and R&D investment.
最後,我們還有數個價值非常高的臨床專案。這並非完整清單。事實上,我們有超過 30 項自辦與合作研究,涵蓋從早期到關鍵性試驗。但這些是今年將帶來最大商業與財務拐點的專案,也是我們在資源配置與研發投資上的優先重點。
I note that 4 out of 5 of these studies are pivotal or Phase 3 studies. We have imminent data point coming out on ProstACT Global, which we will take to the FDA to gain clearance to commence part two in the United States. And I remind you that the study has already progressed to randomizing patients ex-US for part two of the study, and I will talk a little bit about this later in the presentation.
我也要指出,這些研究中有 5 項裡的 4 項屬於關鍵性或第 3 期研究。ProstACT Global 即將公布重要數據,我們將把這些資料提交給 FDA,以取得在美國啟動第二部分研究的許可。也提醒各位,該研究在美國以外地區已進展到為第二部分進行受試者隨機分派;我稍後在簡報中會再多談一些。
Our BiPASS biopsy study will complete enrollment this year and expect to generate significantly enhanced revenue in 2027 as a consequence of this Phase 3 study. Our current latest stage clinical studies paved the way to our first therapeutic commercial inflection point likely in 2028. So these are not distant thoughts. They are all near term catalysts, and I'll come back at the end of presentation to some of the broader sets of upcoming catalysts.
我們的 BiPASS 活檢研究將在今年完成收案,並預期因這項第 3 期研究而在 2027 年帶來顯著提升的營收。我們目前最晚期的臨床研究,正為我們第一個治療性產品的商業拐點鋪路,時間點很可能在 2028 年。所以這些並不是遙遠的想法。它們都是短期催化劑;我也會在簡報最後回到更廣泛的一系列即將到來的催化劑。
Okay. Now Darren, over to you for the numbers.
好的。那麼 Darren,接下來請你說明數字部分。
Darren Smith - Group Chief Financial Officer
Darren Smith - Group Chief Financial Officer
Okay. Thank you very much, Chris. (technical difficulty) we have today reported a 56% growth in revenue to $804 million. This is in line with our up (technical difficulty) revenue guidance -- sorry, someone's muting and unmuting me. Notably this is our third consecutive year of double-digit revenue growth.
好的。非常感謝你,Chris。(技術問題)我們今天公布營收成長 56%,達到 8.04 億美元。這與我們上調的(技術問題)營收指引一致——抱歉,有人一直把我靜音又解除靜音。值得注意的是,這是我們連續第三年達成雙位數營收成長。
Revenue from Precision Medicine business (technical difficulty) year over year. Sorry, can I just ask you, (technical difficulty). Hello?
精準醫療業務的營收(技術問題)年增。抱歉,我可以請你們,(技術問題)。哈囉?
Operator
Operator
Hi, Darren, your line is open. Pardon me, Darren, please check your mute button. Make sure you're not muted on your end.
嗨,Darren,你的線路是開著的。不好意思,Darren,請檢查一下你的靜音鍵。確認你那端沒有被靜音。
Darren Smith - Group Chief Financial Officer
Darren Smith - Group Chief Financial Officer
So this year -- sorry, are you able to hear me now?
所以今年——抱歉,你們現在聽得到我嗎?
Operator
Operator
Hi Darren. Yes, we can hear you. Your line's open.
嗨 Darren。是的,我們聽得到。你的線路是開著的。
Darren Smith - Group Chief Financial Officer
Darren Smith - Group Chief Financial Officer
Okay. Thank you very much. Okay. This is in line with our uplifted full year guidance, and notably, it's our third consecutive year of delivering double-digit growth -- revenue growth. Revenue from our Precision Medicine business increased 22% year over year. With EBITDAR improving 25% to $216 million, driven by strong demand of Illuccix in the launch of Gozellix.
好的。非常感謝。好的。這與我們上調的全年指引一致;值得注意的是,這是我們連續第三年交出雙位數成長——營收成長。我們精準醫療業務的營收年增 22%。EBITDAR 提升 25% 至 2.16 億美元,主要受惠於 Illuccix 的強勁需求以及 Gozellix 的上市推進。
The Precision Medicine commercial performance permitted Telix to self-fund and de-risk our investment into our R&D pipeline and commercial infrastructure to drive future growth. Further, 2025 was a year of significant investment, yet we maintained a solid cash balance of $152 -- $142 million. We achieved this while exercising discipline, cost, management.
精準醫療的商業表現,使 Telix 得以自籌資金並降低我們對研發管線與商業基礎建設投資的風險,以推動未來成長。此外,2025 年是大幅投資的一年,但我們仍維持穩健的現金餘額 1.52——1.42 億美元。我們是在保持紀律、成本與管理控管的同時達成這點。
Next slide, please, which is slide 11. Thank you. We've added slides for our non-accountant investors. At a glance, this slide presents the strength of our business model. The left side of the chart shows our revenue sources in the Materiality. The middle of the graph highlights our gross margin in green. And that 94% of the GM is generated from our Precision Medicine business, that is approximately $400 million.
請看下一張投影片,也就是第 11 張。謝謝。我們為非會計背景的投資人新增了幾張投影片。一眼就能看出,這張投影片呈現了我們商業模式的強度。圖表左側顯示我們在重要性(Materiality)上的營收來源。圖表中間以綠色標示我們的毛利率。其中 94% 的毛利來自我們的精準醫療業務,約為 4 億美元。
As you can see, about half of the gross margin, the red flows heading right, are invested into our commercial [call] and marking capability, our global supply chain in our corporate functions. But more importantly, flowing right at the top half of the gross margin, is approximately $200 million. That's 25% of revenue. And with this, we decide to either invest it in our development pipeline for to create future value or recognizes its operating profit. So as business models go, A business that froze off 25% of revenue as operating profit to reinvest in value creation or to bank Is pretty damn attractive.
如各位所見,約一半的毛利(紅色流向往右)投入到我們的商業[call]與行銷能力、全球供應鏈以及公司職能。但更重要的是,在毛利的上半部往右流動的部分約為 2 億美元。這相當於營收的 25%。我們可用這筆資金選擇投入研發管線以創造未來價值,或將其認列為營業利益。因此,就商業模式而言,一家能把營收的 25% 轉化為營業利益、再投入價值創造或留存的企業,確實非常有吸引力。
Now moving to our traditional P&L. I've spoken to most of the financial highlights from the previous slides. But we'll take some time to talk to further highlight. The group's gross margin of 53% remained consistent with the first half performance. We invested $157 million into product development in line with 2025 guidance and mainly focused on our life stage pipeline.
接著看我們傳統的損益表。前面幾張投影片我已談到大部分財務重點。但我們會再花點時間補充說明。集團毛利率 53%,與上半年表現一致。我們投入 1.57 億美元於產品開發,符合 2025 年指引,且主要聚焦於我們後期階段的研發管線。
General and administration expenses decrease to 12% of revenue from 17% last year, reflecting the efficiencies of scale achieved as the company continues its strong growth trajectory. As a result, we posted an adjusted EBITDA of $39.5 million in line with market consensus.
一般及行政費用占營收比重由去年的 17% 降至 12%,反映公司在持續強勁成長軌跡下所達成的規模效率。因此,我們繳出調整後 EBITDA 3,950 萬美元,符合市場共識預期。
Now moving to our next slide. Telix Precision Medicine business clearly our cash machine. It's financial metrics demonstrate its excellent performance. Precision Medicine delivers an additional $113 million in revenue representing 22% year on year growth alongside a 28% increase in operating profit and a 25% increase in its EBIDTA. This demonstrates the high growth business with capacity to generate significant funds to invest in the long-term value creation.
接著看下一張投影片。Telix 的精準醫療業務顯然是我們的現金機器。其財務指標展現了卓越的表現。精準醫療新增 1.13 億美元營收,年增 22%,同時營業利益成長 28%,EBIDTA 成長 25%。這顯示該高成長業務具備產生大量資金的能力,可用於投資長期價值創造。
Sales in marketing investments supported the launch of Gozellix, the geographic expansion of Illuccix, and the launch readiness activities of Pixclara and Zircaix. As a side comment, if this was a standalone business growing at 20% plus per annum on an extreme (inaudible) value basis, it would be worth up to 8 times revenue. This is a huge value creation for shareholders.
在行銷投資方面的銷售支出,支持了 Gozellix 的上市、Illuccix 的地理擴張,以及 Pixclara 與 Zircaix 的上市準備活動。順帶一提,如果這是一個獨立業務,按每年 20% 以上的成長、以極端(聽不清)價值基礎來看,其估值最高可達營收的 8 倍。這為股東創造了巨大的價值。
Now moving to our next slide on Telix Manufacturing Solutions, or TMS. We've provided this level of detail on TMS in our half year results for two reasons: firstly, to give investors and analysts clear visibility into the financial impact of the RLS acquisition; and secondly to provide transparency into the cost base of the remaining TMS business, helping with financial modeling.
現在切換到下一張投影片:Telix 製造解決方案(Telix Manufacturing Solutions,簡稱 TMS)。我們在本次半年報中提供如此細節的 TMS 資訊有兩個原因:第一,讓投資人與分析師清楚掌握 RLS 併購對財務的影響;第二,提升對剩餘 TMS 業務成本結構的透明度,以利財務建模。
As you can see, RLS delivered positive EBITDA for the first 11 months post-acquisition. At the remaining TMS facilities, we increased the investment compared to last year to permit us to advance operational activity facilitating clinical and commercial supply. As we now close out the full year of having RLS in the business, we will revert back to reporting TMs as one segment for commercial and competitive reasons.
如各位所見,RLS 在併購後的前 11 個月帶來了正向 EBITDA。在其餘 TMS 設施方面,我們相較去年提高了投資,以便推進營運活動,促進臨床與商業供應。隨著我們即將完成 RLS 併入業務的完整年度,出於商業與競爭考量,我們將恢復把 TMS 作為單一部門進行揭露。
Now moving on to cash flow. As you can see in this cash bridge, Telix continued to generate strong operational cash flows, which we then invest into our pipeline. In 2025, Telix generated $206 million from operation, enabling the investment into progressing the (technical difficulty) R&D pipeline. Excluding our last contingent consideration earn out payment of $52 million for Illuccix. We produced the net positive operating cash flow of $35 million.
接著談現金流。如這張現金橋所示,Telix 持續產生強勁的營運現金流,並將其投入我們的產品研發管線。在 2025 年,Telix 由營運產生 2.06 億美元現金,使我們得以投資推進(技術問題)研發管線。若排除 Illuccix 最後一筆或有對價分期支付(earn-out)5,200 萬美元。我們的營運現金流淨額為正 3,500 萬美元。
I reiterate that our investment into R&D is discretionary and can be flexed depending on our commercial performance, permitting us to effectively manage our cash position. Additionally Telix utilize cash on hand to support targeted, strategic investments such as RLS, ImaginAb, and (inaudible). As a result, we ended the year with a prudent cash position of $142 million.
我再次強調,我們對研發的投資具有自主性,可依商業表現彈性調整,使我們能有效管理現金部位。此外,Telix 也運用手上現金支持具針對性、策略性的投資,例如 RLS、ImaginAb,以及(聽不清)。因此,我們在年底維持了審慎的現金部位 1.42 億美元。
Next slide, please. As we prepare for our next phase of growth, we continue shifting allocation of R&D investment into our therapeutic pipeline. In 2026, R&D investment is planned to be in the range of $200 million to $240 million, with the largest allocation directed to the therapeutic development. This highlights our focus to transition to a high-value therapeutic business.
請看下一張投影片。在為下一階段成長做準備之際,我們持續將研發投資的配置轉向治療性產品管線。2026 年的研發投資規劃約為 2.00 億至 2.40 億美元,其中最大部分將投入治療性開發。這凸顯我們聚焦於轉型為高價值的治療性業務。
I'd like to take the opportunity to reiterate our investment strategy. Over the next two to three years, we expect to grow revenues by advancing assets from clinical development to commercialization, expanding indication in geographic reach. We will invest the funds from this commercial growth into our portfolio and ensure that we have the capabilities, infrastructure, and readiness to deliver on our therapeutic programs. Our focus will remain on reinvesting revenues back into the business over the next couple of years, rather than optimizing new term earnings per share.
我想藉此機會再次說明我們的投資策略。在未來兩到三年,我們預期透過推進資產由臨床開發走向商業化、並擴大適應症與地理覆蓋範圍來帶動營收成長。我們將把這些商業成長帶來的資金投入我們的產品組合,並確保具備交付治療性計畫所需的能力、基礎設施與就緒度。未來幾年,我們的重點仍將是把營收再投資回業務,而非優先最佳化短期每股盈餘。
We are committed to building long-term value. We believe prioritizing earnings too early can impede the strategic investments required to fully unlock the potential of our pipeline.
我們致力於打造長期價值。我們相信過早優先追求獲利,可能會阻礙為充分釋放研發管線潛力所需的策略性投資。
Next slide, please. Telix has a disciplined capital allocation approach that is aligned to our corporate strategy. And it has matured a great deal over the last 12 months. We have previously spoken about our four areas of focus, and they are: investing into our R&D, optimizing our commercial performance, strategic growth opportunities through M&A, and supply chain resilience and pro production capacity.
請看下一張投影片。Telix 採取與公司策略一致、且具紀律的資本配置方法。在過去 12 個月中,這套方法已大幅成熟。我們先前談過四個重點領域,分別是:投資研發、優化商業表現、透過併購(M&A)尋求策略性成長機會,以及供應鏈韌性與生產產能。
We believe these four areas of focus will underpin our growth long-term. We have continued to deliver on our strategy in a disciplined way, ensuring that we have a prudent cash back on the balance sheet.
我們相信這四個重點領域將支撐我們的長期成長。我們持續以具紀律的方式落實策略,並確保資產負債表上保有審慎的現金回存。
Next slide, please. Looking forward, we see strong momentum heading into 2026. We have another year of roughly 20%-plus revenue growth anticipated. Our full year 2026 revenue guidance is set at $950 million to $970 million, and this is based on current approved products in approved jurisdictions. This range does not include revenue contributions from pending product approvals, which will be incremental.
請看下一張投影片。展望未來,我們看到進入 2026 年前的強勁動能。我們預期還會有一年約 20% 以上的營收成長。我們對 2026 全年營收的指引為 9.50 億至 9.70 億美元,係基於目前已在核准司法管轄區內獲核准的產品。此區間未包含尚待核准產品所帶來的營收貢獻,該部分將屬增量。
This growth implies up to 25% growth in our Precision Medicine business and a full year of RLS revenue. Our corresponding R&D investment will be in the range of $200 million to $240 million. And will be dependent on the achievement of certain clinical outcomes and development milestones.
這樣的成長意味著我們精準醫療業務最高可達 25% 的成長,並納入 RLS 全年度營收。相對應的研發投資將落在 2.00 億至 2.40 億美元之間。並將取決於特定臨床結果與開發里程碑的達成情況。
In conclusion, we delivered another year of double-digit revenue growth, made high-value strategic investments across the business in maintained a prudent cash position. Looking ahead, 2026 is set to be an inflection year with numerous important milestones. Our revenue guidance reflects the confidence we have in the business and we remain committed to disciplined financial management throughout 2026.
總結而言,我們再度交出雙位數營收成長的一年,並在全公司進行高價值的策略性投資,同時維持審慎的現金部位。展望未來,2026 年將是拐點之年,將有多項重要里程碑。我們的營收指引反映了我們對業務的信心,且我們仍將在 2026 年全年度堅持具紀律的財務管理。
I'll now hand you over to Kevin Richardson, Precision Medicine CEO. Thank you.
接下來我把時間交給精準醫療執行長 Kevin Richardson。謝謝。
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Thank you, Darren. My first slide, please. Last year, our Precision Medicine portfolio delivered $622 million in revenue, up 22% year over year. Importantly, we delivered sequential growth every single quarter. That includes Q3, our most challenging quarter, which was the first full quarter following the expiration of a Illuccix transitional pass-through status and the transition to MUC, M-U-C or mean unit cost reimbursement for a subset of Medicare patients. Q3 allowed us to see the full impact of that change on the business.
謝謝你,Darren。請看我的第一張投影片。去年,我們的精準醫療產品組合營收為 6.22 億美元,年增 22%。重要的是,我們在每一季都實現了逐季成長。其中包括第三季——我們最具挑戰的一季——那是 Illuccix 過渡性 pass-through 身分到期後的第一個完整季度,並且針對部分 Medicare 病患轉為 MUC(M-U-C,平均單位成本)給付。第三季讓我們看到了這項變更對業務的完整影響。
Even in that environment, and despite ongoing competitive pressure, we still delivered 3% quarter of a quarter dose growth and 1% sales growth. That performance speaks to our disciplined approach to business fundamentals and the strength of our customer facing team. We continue to gain share based on clinical differentiation and operational reliability. Our PSMA agents demonstrates fewer indeterminate bone lesions and higher inter-reader agreement compared to F-18 assets, driving confidence in clinical decision making.
即便在那樣的環境下,且儘管競爭壓力持續,我們仍實現了劑量逐季成長 3%,以及銷售成長 1%。這樣的表現反映了我們對業務基本面的紀律性做法,以及我們面向客戶團隊的實力。我們持續憑藉臨床差異化與營運可靠性來提升市占。與 F-18 產品相比,我們的 PSMA 製劑呈現較少的不確定骨病灶,且讀片者間一致性更高,進而提升臨床決策的信心。
We pair that clinical value with highly specialized commercial organization that engages customers every day and consistently differentiates Telix in the market. Our reputation as an innovator also positioned us for a successful launch of Gozellix. Gozellix was FDA-approved in April of 2025, and transitional pass-through status became effective in October, enabling a transitional pass-through supported, full launch in Q4 of 2025. We are very pleased with the update and our 2026 full year guidance underscores our strong conviction in the growth outlook for our Precision Medicine portfolio.
我們將這項臨床價值與高度專業化的商業組織相結合,該組織每日與客戶互動,並持續在市場上清楚區隔 Telix。我們作為創新者的聲譽,也使我們得以成功推出 Gozellix。Gozellix 於 2025 年 4 月獲 FDA 核准,而過渡性 pass-through 身分於 10 月生效,使得 2025 年第四季得以在過渡性 pass-through 支持下全面上市。我們對進展感到非常滿意,而我們對 2026 全年指引也凸顯了我們對精準醫療產品組合成長前景的強烈信心。
Today, we are the only company with two PSMA agents on the market. This dual product strategy is a competitive advantage, offering different types of customers meaningful choice across economics and scheduling flexibility, while reinforcing our commitment to meeting diverse clinical and operational needs. In short, resilient growth, clinical differentiation, disciplined execution and a platform built for sustained growth.
目前,我們是市場上唯一同時擁有兩款 PSMA 製劑的公司。這項雙產品策略是一項競爭優勢,能在經濟性與排程彈性方面為不同類型客戶提供有意義的選擇,同時強化我們滿足多元臨床與營運需求的承諾。簡而言之:具韌性的成長、臨床差異化、具紀律的執行,以及為持續成長而打造的平台。
Next slide, please. What does it take to win in a maturing PSMA market? Winning in a mature PSMA market is no longer about being first. It's about executing its scale.
請看下一張投影片。在逐漸成熟的 PSMA 市場中,勝出需要什麼?在成熟的 PSMA 市場中取勝,不再是關於誰先進入市場。而是關於以規模化來執行。
Clinical credibility is non-negotiable. Products must deliver consistently high image quality, strong inter-reader agreement and reliable detection at low PSA levels across all patient types. Incremental claims aren't enough. Confidence in clinical decision making is what sustains adoption. Workflow integration matters. In a high volume market, solutions must fit seamlessly into established clinical pathways, enable same-day imaging and support high patient throughput without disrupting nuclear medicine operations.
臨床可信度是不容妥協的。產品必須在所有患者類型中,即使在低 PSA 水準下,也能持續提供高影像品質、強勁的閱片者間一致性,以及可靠的檢出能力。僅有漸進式的主張並不足夠。能支撐採用的,是對臨床決策的信心。工作流程整合同樣重要。在高量市場中,解決方案必須無縫融入既有臨床路徑、支援當日成像,並在不干擾核醫作業的情況下支援高病患吞吐量。
Reimbursement sophistication is a competitive advantage. Success requires multiple product strategies that give customers economic flexibility while navigating complex and evolving reimbursement frameworks over extended period of times. Commercial infrastructure is a must. This is a contract-driven market that demands experience field teams, market access expertise, compliance rigor and long-standing customer relationships. These capabilities take a large investment in years, not quarters to build.
報銷(給付)策略的成熟度是一項競爭優勢。成功需要多元的產品策略,使客戶在面對複雜且持續演變的報銷框架、並在長時間期間內運作時,仍能保有經濟上的彈性。商業化基礎設施是必需的。這是一個以合約驅動的市場,要求具經驗的前線團隊、市場准入專業、嚴謹的合規管理,以及長期的客戶關係。這些能力需要多年、而非幾個季度的大量投資才能建立。
Supply chain excellence separates winners from participants. Reliable, flexible dose production and delivery at scale supported by higher nuclear pharmacy last mile experts is critical. There is no proven shortcut to mass market large volume coverage. Sustained investment fuels durability. Indication expansion, life cycle management and camera type technology advances all require ongoing clinical and operational investment to maintain leadership. In short, leadership in PSMA is earned through clinical trust, operational reliability, commercial scale and disciplined investment, not novelty.
供應鏈卓越將勝出者與參與者區分開來。在更高階的核藥房「最後一哩」專家支援下,具備可靠、彈性且可規模化的劑量生產與配送至關重要。要在大眾市場達成大規模、高量覆蓋,沒有已被證實的捷徑。持續投資帶來長期韌性。適應症擴展、產品生命週期管理,以及相機類型的技術進步,都需要持續的臨床與營運投資以維持領先。總之,PSMA 的領導地位是透過臨床信任、營運可靠性、商業規模與紀律投資所贏得,而非靠新奇。
Next slide, please. We continue to execute our strategic plan to grow the Precision Medicine business by expanding our product offering, expand our indications on those products and expand the geographies where we market those products. Global expansion is a priority for Precision Medicine here at Telix.
請看下一張投影片。我們持續執行策略計畫,透過擴大產品組合、擴展這些產品的適應症,以及擴大我們行銷這些產品的地理市場,來推動精準醫療業務成長。在 Telix,精準醫療的全球擴張是優先事項。
Illuccix is now available in 17 countries with reimbursement secured, and we hold marketing authorizations in more than 24 markets. In 2025, we focused on country by country Access. In '26, we pivot to driving upptake, particularly across key markets, including the UK, France, Germany, Italy and Spain.
Illuccix 目前已在 17 個國家上市且已取得給付,並且我們在超過 24 個市場持有行銷許可。2025 年,我們聚焦於逐國取得准入。到了 2026 年,我們將轉向推動採用率,特別是在英國、法國、德國、義大利與西班牙等關鍵市場。
In China, we delivered strong Phase 3 results with 94.8% positive predictive value, including patients with very low PSA levels. We've submitted the NDA to the regulators with our partner Grand Pharma, and with prostate cancer incidence rising in PET/CT infrastructure expanding rapidly, China represents a significant growth opportunity.
在中國,我們取得強勁的第三期結果,陽性預測值達 94.8%,其中包含 PSA 非常低的患者。我們已與合作夥伴 Grand Pharma 向監管機構提交 NDA(新藥申請)。隨著前列腺癌發生率上升、PET/CT 基礎設施快速擴張,中國代表一個重大的成長機會。
While in Japan, our 105 patient Phase 3 study is progressing well with the first patient dose. This positions us well in the world's second largest pharmaceutical market where prostate cancer remains a leading cause of mortality. New products and new indications enhance our ability to take share and grow the market. And Gozellix is off to a strong start, and we are focused on accelerating commercial momentum in 2026, and you can see that is reflected in our 2026 guidance.
在日本,我們的 105 名患者第三期研究進展順利,且已完成首位患者給藥。這使我們在全球第二大藥品市場中具備良好定位,而前列腺癌仍是主要死亡原因之一。新產品與新適應症提升我們搶占市佔並擴大市場的能力。Gozellix 也有一個強勁的開局;我們聚焦於在 2026 年加速商業動能,而你們可以在我們的 2026 年指引中看到這點有所反映。
BiPASS is a Phase 3 study that represents the next wave of innovation, combining PSMA imaging, Illuccix or Gozellix with MRI to improve diagnostic accuracy and potentially reduce or eliminate invasive biopsies. This is about moving earlier in the care pathway, reducing patient risk, lowering system costs and expanding the total addressable market to include frontline biopsy candidates. We believe moving to the front line where patients are diagnosed (inaudible) competitive advantage, both as the lead PSMA in diagnosis but also in sequential scans that happen later on in the patient journey as physicians want to see consistency scan to scan.
BiPASS 是一項第三期研究,代表下一波創新:將 PSMA 影像(Illuccix 或 Gozellix)與 MRI 結合,以提升診斷準確性,並可能減少或免除侵入性切片。這是要在照護路徑中更早介入,降低患者風險、降低系統成本,並將可服務總市場擴大至第一線切片候選者。我們相信,前移到患者被診斷的第一線(聽不清)是一項競爭優勢:不僅能成為診斷端的領先 PSMA,也能在患者旅程後續的序列掃描中受益,因為醫師希望每次掃描之間保持一致性。
For Zircaix, we've completed two type A meetings with the FDA and believe we have full alignment on key resubmission requirements. We are now focused on completing the agreed deliverables and documentation required for the resubmission. With breakthrough therapy designation, supportive ZIRCON-X data and the inclusion in major international guidelines, this remains a top priority for approval and launch this year. This is a really exciting and highly anticipated product.
關於 Zircaix,我們已與 FDA 完成兩次 A 類會議,並相信我們已就重新提交的關鍵要求達成完全一致。我們目前專注於完成已同意的交付項目與重新提交所需的文件。憑藉突破性療法認定、支持性的 ZIRCON-X 數據,以及納入主要國際指引,這仍是我們今年核准與上市的最高優先事項之一。這是一款非常令人振奮且備受期待的產品。
Moving on to our neuro platform. We are pursuing complimentary submissions in both the EU and the US. TLX101-Px was filed with the European regulators recently, and the US submission will follow closely. As a reminder, the FDA has granted both orphan drug and fast track designation for Pixclara. Our commercial, medical, and supply chain teams are launch-ready. Our expanded access programs serve patients and our customers very well, and they anticipate commercial use of Pixclara.
接著談我們的神經平台。我們正推進在歐盟與美國的同步(互補)申報。TLX101-Px 近期已向歐洲監管機構遞交,美國申報也將緊接著進行。提醒一下,FDA 已授予 Pixclara 孤兒藥與快速通道資格。我們的商業、醫學與供應鏈團隊已做好上市準備。我們的擴大使用計畫(expanded access programs)為患者與客戶提供了很好的服務,他們也期待 Pixclara 的商業化使用。
In short, we built a global commercial platform, delivered successful launches, taken share, penetrated the available market and advanced multiple late-stage assets in high, unmet needs markets. We are entering our next phase of growth with momentum and discipline.
總之,我們建立了全球商業平台,成功完成多次上市,取得市佔、滲透可及市場,並在高未滿足需求的市場推進多項後期資產。我們正以動能與紀律進入下一階段的成長。
Next slide, please. So what is this strategy mean in terms of financial impact? Our current baseline business with some further life cycle management, which we've talked about, should be able to [sustain] a 15% to 20% annualized growth. This partially reflects the growth of the (inaudible) overall, as well as our ability to continue to capture market share as the size of the market expands. The recent addition of Gozellix certainly de-risked this.
請看下一張投影片。那麼,這項策略在財務影響上代表什麼?我們目前的基礎業務,加上一些我們已談過的進一步生命週期管理,應可[維持]每年 15% 到 20% 的年化成長。這部分反映了(聽不清)整體的成長,以及在市場規模擴大時我們持續取得市佔的能力。近期加入的 Gozellix 確實降低了這方面的風險。
With indication expansion in prostate cancer alone, particularly a major opportunity in the BiPASS study, this growth over the five years can be closer to a 30% CAGR. And then when you add in Pixclara and Zircaix, this growth rate defensively looks more like 40% compounded annual growth, especially with metastatic indication expansions that further drive procedural volume. In short, our current product strategy, which is fully baked from a clinical perspective, just needs to clear a few more regulatory hurdles as it represents future upside for the company. It is a direct consequence of the market presence we are building, the depth of our pipeline, and the quality of service we are able to deliver to the patients.
僅以前列腺癌的適應症擴展而言,特別是 BiPASS 研究中的重大機會,這五年期間的成長可更接近 30% 的年複合成長率(CAGR)。再加上 Pixclara 與 Zircaix,從風險防禦角度看,成長率更像是 40% 的年複合成長,尤其是在轉移性適應症擴展進一步帶動檢查量的情況下。總之,我們目前的產品策略在臨床面已完全成熟,只需再跨過幾個監管門檻,便可為公司帶來未來上行空間。這是我們正在建立的市場存在感、產品線深度,以及我們能為患者提供的服務品質所直接帶來的結果。
This is really an exciting business with a bright future. The growth in Precision Medicine gives us the ability to finance the growth potential of our therapeutics business.
這確實是一項令人振奮、前景光明的業務。精準醫療的成長讓我們有能力為治療業務的成長潛力提供資金。
And on that note, I'll hand It back over to Chris to give you a bit of perspective on that.
基於這點,我把時間交回給 Chris,請他就此提供一些觀點。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Thanks very much, Kevin. Great update and congratulations on all the success that your team had this year. It was a really remarkable year of accomplishment.
非常感謝你,Kevin。更新得很好,也恭喜你和你的團隊今年取得的所有成功。這真的是成果斐然的一年。
Okay. So moving on slide 25, please. In a way, this slide is a simplified version of my opening slide. A highly profitable cash generative business that would garner, as Darren said, a very healthy revenue multiple if it was a standalone business. But it's our engine room, and the future growth trajectory of the business will come from how that cash is invested.
好的。那麼請看第 25 張投影片。某種程度上,這張投影片是我開場投影片的簡化版。這是一個高度獲利、能產生現金的業務;正如 Darren 所說,如果它是一個獨立業務,將會獲得非常健康的營收倍數。但它是我們的引擎室,而公司未來的成長軌跡將取決於這些現金如何被投資。
Kevin's already shown you very clearly, I think, how the Precision Medicine business alone can grow expansively over the next five years based on clinical, regulatory and commercial inflection points that we expect to achieve this year. Again, I just want to reemphasize the point that the growth trajectory that Kevin has talked about comes from events that will be completed this year.
Kevin 已經非常清楚地向各位展示,我認為,僅精準醫療業務就能在未來五年大幅成長,這是基於我們預期今年將達成的臨床、監管與商業拐點。我再次想強調,Kevin 所談到的成長軌跡,來自於今年將完成的事件。
I think it's also important to reinforce our commitment to manufacturing and supply chain, but in the context of our Therapeutics business, it's more than just reliable and on-time dose delivery. It's about R&D cost and efficiency and perhaps most importantly, intellectual property capture. We've learned over the last decade that when you use contract manufacturing organizations, your product scale up that we simply educate the ecosystem in a way that potentially empowers competition, and we no longer wish to do that.
我認為同樣重要的是,要強化我們對製造與供應鏈的承諾;但在我們治療(Therapeutics)業務的脈絡下,這不僅僅是可靠且準時的劑量交付。這關乎研發成本與效率,更重要的或許是智慧財產的掌握。過去十年我們學到,當你使用委外製造機構(CMO)時,在產品放大規模的過程中,我們其實是在以某種方式教育整個生態系,可能反而賦能競爭者,而我們不再希望這樣做。
So, especially as our Therapeutics go into late stage trials, this has become an important strategic objective of the company. To be clear, we still use CMOs, but where there's key IP around platforms, targeting agents and certain key isotopes, we are increasingly tackling this in-house or with selected partners.
因此,特別是當我們的治療產品進入後期臨床試驗時,這已成為公司一項重要的策略目標。說清楚一點,我們仍然會使用 CMO,但在涉及平台、標靶載體以及某些關鍵同位素等核心智慧財產的部分,我們愈來愈多改為內部承擔,或與特定合作夥伴共同推進。
Moving on to the next slide, please. And this slide shows the reason why. As I've said, Kevin has already talked about what share of the Precision Medicine side of the business. We think we can tackle over the next five years or so. And on a TAM base, it's actually pretty conservative.
請翻到下一張投影片。這張投影片顯示了原因。如我所說,Kevin 已經談到精準醫療(Precision Medicine)這一端的業務,我們認為未來五年左右可以切入的市場份額。我們認為在未來五年左右可以處理/切入。而以總可服務市場(TAM)為基礎來看,其實相當保守。
But the Therapeutics opportunity is about 3 or 4 times bigger for the targets and indications that we are already pursuing. This doesn't even capture the potential for indication expansion into new disease areas that some of the panc cancer targets we are developing, like Carbonic anhydrase IX and (inaudible) can potentially expand into. So it's a really bright future for the theranostic strategy.
但就我們已在追求的標的與適應症而言,治療(Therapeutics)的機會大約是其 3 到 4 倍。這甚至還未納入我們正在開發的一些泛癌標的(pan-cancer targets)在新疾病領域擴展適應症的潛力,例如碳酸酐酶 IX(Carbonic anhydrase IX)以及(聽不清)等,可能都能擴展到其他領域。因此,對於診療一體(theranostic)策略而言,未來非常光明。
Moving on to slide 27, please. Over the last five years, we've built a very strong pipeline with some key disease focus areas, and you're going to increasingly hear us talk about these disease areas as multi-product concentration areas. Frankly, much as we have done with Gozellix and Illuccix on the Precision Medicine side of the business, indeed, to tackle some of these major unmet clinical needs, it's going to in some cases require a multi-asset approach at different stages in the clinical development or in the clinical patient journey. And so -- and also, well-considered combination therapies with standard of care medical oncology.
請翻到第 27 張投影片。過去五年,我們建立了非常強的產品管線,聚焦於一些關鍵疾病領域;你們將會愈來愈常聽到我們把這些疾病領域稱為「多產品集中領域」。坦白說,就像我們在精準醫療業務端以 Gozellix 與 Illuccix 所做的一樣,為了因應一些重大的未被滿足臨床需求,在某些情況下,將需要在臨床開發不同階段或在臨床病患旅程不同環節,採取多資產(multi-asset)的策略。此外,也需要與標準治療(standard of care)的腫瘤內科療法進行經過審慎設計的合併治療。
This is evident already, for example, in the design of the ProstACT Global and IPAX BrIGHT studies. There are three particular attributes of our pipeline that I'd like to specifically comment on. Firstly, by taking a the gnostic approach, we build a very deep relationship with the referral and prescribing physician in each of these disease areas. This is a competitive advantage, and this relationship depth has already started with our existing commercial product portfolio and will only intensify over the next 12 months. Investors often view the Precision Medicine and Therapeutics business areas is adjacent, but they are clearly not.
例如,這點已經反映在 ProstACT Global 與 IPAX BrIGHT 研究的設計中。我們的管線有三個特別的屬性,我想特別說明。第一,透過採取診療一體(theranostic)的方法,我們能在各個疾病領域與轉診及開立處方的醫師建立非常深厚的關係。這是一項競爭優勢,而這種關係深度已經從我們現有的商業化產品組合開始建立,並且在未來 12 個月只會更加深化。投資人常把精準醫療與治療兩個業務領域視為相鄰,但它們顯然不是。
Secondly, while we have some very high potential early stage programs, and this is not exhausted this list because we have a pretty decent preclinical portfolio coming in behind. We have three late-stage programs in prostate, renal and glioblastoma that will generate significant data over the next 12 months. Based on current valuation of the company, these programs are essentially a free option, but we think that the data and clinical basis of these programs are very compelling.
第二,雖然我們有一些潛力非常高的早期專案,而且這份清單也尚未涵蓋全部,因為後面還有相當不錯的臨床前產品組合在跟進。我們在前列腺癌、腎癌與膠質母細胞瘤(glioblastoma)有三個後期專案,將在未來 12 個月產出大量重要數據。以公司目前估值來看,這些專案基本上等同於一個免費選擇權,但我們認為其數據與臨床基礎都非常有說服力。
Most importantly, while 2026 And 2027 financials will reflect the commercial expansion of the Precision Medicine business, 2028 is our commercial launch year for our Therapeutics business. So it's not far away. This is why we have so much execution focus on the (technical difficulty) targets learning about disease extent, exploring new patient populations, and ultimately, increasing the market size and market share.
最重要的是,雖然 2026 與 2027 年的財務表現將反映精準醫療業務的商業化擴張,但 2028 年將是我們治療(Therapeutics)業務的商業上市年份。因此並不遙遠。這也是為什麼我們在執行上高度聚焦於(技術難度)標的:加深對疾病範圍的理解、探索新的病患族群,並最終擴大市場規模與市占率。
So the Therapeutics, when they become available, the Precision Medicine business will pave the way. And so notwithstanding a few challenging but also educational regulatory speed bumps we've had, our commercial image report gives us the skills and confidence that we can deliver on the Therapeutic programs in the future. We've learned a lot this year, especially last year.
因此,當治療產品可用時,精準醫療業務將為其鋪路。所以,儘管我們遇到了一些具挑戰性但也具教育意義的法規進度顛簸,我們的商業化經驗讓我們具備技能與信心,未來能交付治療專案。今年我們學到很多,尤其是去年。
Can you hear me okay? All right. Moving on to the next slide, please. As I noted earlier, we have many different clinical studies running. Some companies sponsored, some in collaboration with key opinion leaders around the globe.
你們聽得到我嗎?好。請翻到下一張投影片。如我先前提到,我們正在進行許多不同的臨床研究。有些由公司主導,有些則與全球關鍵意見領袖合作進行。
But the four major trials to watch this year are outlined here. I'm not going to go blow by blow on this because this is an earnings call, but I think it's important for shareholders to understand where the research priorities are and what the development goals and catalysts are. We are collecting a ton of patient data this year, and it's very exciting to have three programs in pivotal studies. This is important for patients and important for shareholders, and it's taken a lot of work and investment to get here.
但今年最值得關注的四項主要試驗在這裡列出。我不會逐項細講,因為這是財報電話會議,但我認為讓股東了解研究優先順序、開發目標與催化劑所在非常重要。今年我們正在收集大量病患數據,而有三個專案進入關鍵性(pivotal)研究,令人非常振奮。這對病患很重要,對股東也很重要,而走到這一步投入了大量工作與投資。
Moving on to slide 29. Of course, front of mind for patients and shareholders alike is a ProstACT Global study. This study is now recruiting into Part Two randomized part of the study ex-US, and is ramping up very nicely. Unlike Part One, which is safety do symmetry run-in study that the FDA required in order for us to include US patients in the randomized part of the study, Part two is very streamlined and straight forward.
請翻到第 29 張投影片。當然,病患與股東最關心的,是 ProstACT Global 研究。這項研究目前正在美國以外地區招募第二部分的隨機分組研究,且推進得非常順利。不同於第一部分(第一部分是 FDA 要求的安全性劑量測定導入研究,以便我們能在隨機分組部分納入美國病患),第二部分的設計更精簡且更直接。
Part Two commenced recruitment last year following an independent data safety review that determined that Part One data met pre-specified safety criteria to progress. We will be shortly releasing the details of the Part One study concurrent with our submission to the FDA to request approval to add US patients into the study.
在獨立的數據安全性審查判定第一部分數據符合預先設定的安全性標準、可進入下一階段後,第二部分於去年開始招募。我們將在向 FDA 提交申請、請求核准將美國病患納入研究的同時,於近期公布第一部分研究的細節。
Looking forward to getting these results out into the market and to show the great progress we are making. Particularly given the unique combination therapy design of the ProsACT Global study. To remind you, the data we will be putting out from Part One will be safety data on the three standard of care combinations in the Global study, as well as comparative dosimetry data, which will be very interesting to see, particularly for the two different androgen deprivation therapies used in the study. So this is coming soon.
我們期待把這些結果推向市場,並展示我們正在取得的重大進展。尤其考量 ProstACT Global 研究獨特的合併治療設計。提醒各位,我們將公布的第一部分數據,將包含 Global 研究中三種標準治療合併方案的安全性數據,以及比較性的劑量測定(dosimetry)數據;這將非常值得關注,特別是研究中使用的兩種不同雄激素剝奪療法(androgen deprivation therapies)。因此很快就會公布。
Moving on to slide 30. Before I wrap up with a summary of the catalysts, I thought I would share a montage of patient case studies to really tie together the company's strategy and illustrate how integrated the Precision Medicine, Therapeutics and Manufacturing businesses are. In short, why we are here.
請翻到第 30 張投影片。在我用催化劑摘要作結之前,我想分享一組病患個案的拼圖(montage),以真正把公司的策略串聯起來,並說明精準醫療、治療與製造三大業務是如何高度整合。簡言之,這就是我們在這裡的原因。
This slide illustrates four patients in four different cancers, all of which are advanced, extremely difficult to treat cases. Every day across the entire portfolio, we see examples of where our development and commercial pipeline changes lives. Sometimes it's a better understanding of the extent of disease. Sometimes it's a profound disease modification, such as the metastatic prostate and breast cancer examples on this slide. Other times it's the glioblastoma or the kidney cancer patient that had stabilized disease or enough reduction in pain to be able to return to work.
這張投影片呈現四位不同癌症的病患,且全都是晚期、極難治療的案例。每天在整個產品組合中,我們都看到我們的開發與商業化管線改變生命的例子。有時是更好地理解疾病的範圍。有時是顯著的疾病改變,例如本投影片中的轉移性前列腺癌與乳癌案例。其他時候則是膠質母細胞瘤或腎癌病患,疾病獲得穩定,或疼痛減輕到足以重返工作。
These are the real outcomes from our research, and they deliver profound and life changing outcomes for patients. This is what motivates us and why we believe that investing our hard-earned cash into this future is so important. The technology works and will get better as we learn more and get more clinical experience. I'm also obliged to point out that for the most part, what you're seeing here are images created with the companion diagnostic imaging agent that we are also developing and highlights that this -- that not only is imaging technology critical for diagnosing and staging patients, but will play a fundamental role in predicting and measuring disease control as well.
這些是我們研究得出的真實結果,並為病患帶來深遠且改變人生的成效。這正是驅動我們的動力,也是在我們看來,將辛苦賺來的資金投資在這個未來如此重要的原因。這項技術是可行的,而且隨著我們學到更多並累積更多臨床經驗,還會持續進步。我也有義務指出,您在這裡看到的多數影像,是使用我們同時在開發的伴隨診斷影像試劑所產生的;這也凸顯出——影像技術不僅對病患的診斷與分期至關重要,也將在預測與衡量疾病控制方面扮演根本性的角色。
Okay. Moving to the last slide. To wrap up, this slide summarizes the year ahead. It is a big year with many inflection points across the entire business. I will not go line by line, but we have a lot to talk about in 2026 with the next three major catalysts being resubmission of Pixclara and, of course, Zircaix, and the release of the Part One Global data. We are looking forward to delivering these important milestones to patients and shareholders as the year progresses.
好的。我們來到最後一張投影片。總結來說,這張投影片概述了未來一年的重點。這將是重要的一年,整個業務將出現許多關鍵轉折點。我不會逐條說明,但在 2026 年我們有很多可以談的內容,接下來三個主要催化劑分別是 Pixclara 的重新遞交,當然還有 Zircaix,以及第一部分全球數據的發布。隨著年度推進,我們期待為病患與股東交付這些重要里程碑。
With that, I will pause and hand it over for questions.
說到這裡,我先暫停,接下來交給大家提問。
Operator
Operator
(Operator Instructions) Laura Sutcliffe, Citi.
(接線員指示) Citi 的 Laura Sutcliffe。
Laura Sutcliffe - Equity Analyst
Laura Sutcliffe - Equity Analyst
Thank you for taking my question. At the risk of potentially making myself a bit unpopular, I think we'd like to understand a bit more about when we might see some data for 5912, the safety data. And perhaps given that you've said you will disclose at the same time that you go to the FDA whether the next steps are things that you need to do at Telix, or whether you're waiting for the FDA to do something on their end to be able to get to that point.
謝謝讓我提問。冒著可能讓自己有點不受歡迎的風險,我想我們希望更了解一下,何時可能會看到 5912 的一些數據,尤其是安全性數據。另外,鑑於您提到會在向 FDA 提交的同時對外披露,想請教接下來的步驟是 Telix 需要完成的事項,還是您在等待 FDA 端採取某些行動,才能走到那一步。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah. Hi Laura, thanks for your question. It's not a bad question or an unpopular question at all. So we have had an Independent Data Safety Review Board that has under the clinical charter of the study has reviewed the data and progressed to randomization ex-US. However, in order for us to send the information to the FDA and disclose the information publicly, we need to just to complete the clinical case report forms and formally close out and -- quality control and validate the data, because that's obviously what the FDA wants to see.
是的。嗨 Laura,謝謝你的問題。這不是個不好的問題,也完全不是不受歡迎的問題。我們有一個獨立的資料安全審查委員會(Independent Data Safety Review Board),依照該研究的臨床章程已審查數據,並推進到美國以外地區的隨機分派。不過,為了把資訊送交 FDA 並對外公開披露,我們需要完成臨床病例報告表(CRF),並正式結案——進行品質控管與數據驗證,因為這顯然是 FDA 希望看到的。
As soon as we have that data -- and I haven't seen it, I'm not privy to it, but as soon as it's available, we will simultaneously disclose it and submit it to the FDA. So we're not waiting on anything from the FDA. It's all on the company side and you will not have long to wait.
一旦我們拿到那些數據——我還沒看過,我也無法接觸到——但只要可用,我們會同時對外披露並提交給 FDA。所以我們不是在等 FDA 方面的任何事情。全部都在公司端,你們不需要等太久。
Operator
Operator
Thank you. Our next question comes from Tara Bancroft with TD Cowen. Your line is open.
謝謝。下一個問題來自 TD Cowen 的 Tara Bancroft。您的線路已開通。
Unidentified Participant
Unidentified Participant
Great. Thanks very much for taking our question. This is Nick on for Tara. Congrats on the progress and the strong guidance for 2026. We we're hoping that you can dive in a little more into what you've seen in the early innings of the two products strategy for Illuccix and Gozellix, and how you anticipate that will evolve this year to reach the 25% growth in the Precision Medicine revenue. Thanks.
太好了。非常感謝讓我們提問。我是 Nick,代 Tara 提問。恭喜你們的進展,以及對 2026 年提出強勁的指引。我們希望你們能更深入談談,在 Illuccix 與 Gozellix 的雙產品策略早期階段你們看到了什麼,以及你們預期今年這個策略會如何演進,以達成精準醫療(Precision Medicine)營收 25% 的成長。謝謝。
Darren Smith - Group Chief Financial Officer
Darren Smith - Group Chief Financial Officer
Yeah. Hi, thanks very much for the question. Kevin, do you want to pick this one up for your wheelhouse?
好的。非常感謝你的問題。Kevin,你要不要就你熟悉的領域來回答這題?
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Sure. Yeah, thank you for the question. So the two product strategy is -- enables us to really manage the economic need of [ops] accounts and the way that they perceive and their preference for a reimbursed product over really a non-reimbursed product. As you know, MUC or main unit cost, has really kind of changed the environment and the reimbursement environment there, as well as the way that the pricing happens in the ops accounts. So being able to have a two product company enables us to manage that particular customer type and the self standing or we call them IDTF group, in a different way as we manage the the preference they have for a reimbursement price or one that might be a little more price sensitive.
當然。是的,謝謝你的問題。雙產品策略——讓我們能真正管理 [ops] 客戶帳戶的經濟需求,以及他們如何看待並偏好「可獲得給付」的產品,而不是「未獲給付」的產品。如你所知,MUC(或主單位成本,main unit cost)確實改變了那裡的環境與給付環境,也改變了在 ops 客戶帳戶中定價的方式。因此,作為一家擁有兩項產品的公司,使我們能以不同方式管理這類客戶,以及獨立營運的——我們稱之為 IDTF 群體——並因應他們對給付價格的偏好,或對價格更敏感的偏好。
So -- and then of course we have a longer view of the Precision Medicine business and PSMA specifically, as we think through what over time can happen and what will happen with CMS as they continue to evolve and change reimbursement. So that it enables us to kind of manage the ASP if you will, as the CMS may or look more towards the ASP reimbursement model. So it gives us options in the future without locking down a singular product on that.
此外,當我們思考精準醫療業務、特別是 PSMA 隨時間可能發生與將會發生的變化時,我們也有更長期的視角,並考量 CMS 在持續演進與調整給付時的影響。因此,這讓我們能在某種程度上管理 ASP(平均銷售價格),因為 CMS 可能會、或更傾向於採用 ASP 給付模式。所以,這讓我們在未來有更多選項,而不必被單一產品所綁定。
Operator
Operator
Shane Storey, Canaccord Genuity.
Canaccord Genuity 的 Shane Storey。
Shane Storey - Analyst
Shane Storey - Analyst
Good morning, everyone. Kevin, I'm going to stick with you, if that's okay. Question on Pixclara, just maybe some descriptive piece, I guess, around the customer channel there. It's quite different from your PSMA urology presence. Is that potentially a first work example for how the Varian relationship might evolve. Just some thoughts on that, please.
各位早安。Kevin,如果可以的話,我想繼續問你。關於 Pixclara 的問題,可能想請你描述一下那邊的客戶通路。這和你們在 PSMA 泌尿科領域的布局很不一樣。這是否可能是 Varian 合作關係未來如何演進的第一個實例。請分享一些看法,謝謝。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Kevin, are you there?
Kevin,你在線上嗎?
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Yeah. So I'll take that first then, Chris. So, Varian is -- we're really excited about the possibilities in that. A lot focused, of course, on PSMA and Illuccix, Gozellix. And so, we're -- as we think about that from a commercial perspective, we have a what we call a ninja team.
在。那我先回答這題,Chris。我們對 Varian 的各種可能性非常興奮。當然,很多重點聚焦在 PSMA 以及 Illuccix、Gozellix。因此,從商業角度來看,我們有所謂的「ninja team」。
As you know, there's not as many sites as there are that do PSMA prostate scanning as there are that are going to do neuro scanning. So we have a smaller team that's focused on the referral, the neurologist, and the idea behind that is we already had the relationship at the new med level. So we're able to drive those patients into the scanner, if you will, and then we have a team that already has the relationships at the other end of that where they're reading it.
如你所知,能做 PSMA 前列腺掃描的站點數量,和將要做神經掃描的站點數量並不一樣。所以我們有一個較小的團隊,專注在轉診端、神經科醫師;其背後的想法是,我們在核醫層級(nuclear medicine level)本來就已有合作關係。因此我們能把病患導入掃描端;同時在另一端——也就是判讀影像的端點——我們也已有團隊建立了關係。
So the idea is it's a referral and then into the existing relationship, we have at the nuclear medicine site. And, of course, if that is not a Illuccix or Gozellix side, it gives us good access into those sites, and it's a real competitive advantage to be able to offer these more orphan drug type technologies because of that.
所以概念是:先轉診,然後導入我們在核醫站點既有的合作關係。當然,如果那不是 Illuccix 或 Gozellix 的站點,這也讓我們能很好地切入那些站點;而且由於這點,我們能提供這些更偏孤兒藥類型的技術,形成真正的競爭優勢。
Did that answer your question, Shane? Okay. Chris, anything to add?
這有回答你的問題嗎,Shane?好的。Chris,你有要補充的嗎?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
All right. No, that's good. We'll move on to the next question, please.
好。沒有,這樣很好。我們請下一個問題。
Operator
Operator
David Stanton, Jefferies.
Jefferies 的 David Stanton。
David Stanton - Analyst
David Stanton - Analyst
Good morning, team, and thanks very much for taking my question. It's -- I might be flogging a dead horse here, but I just want to make it clear and help you to make it clear, you'll be reinvesting earnings to get close to zero impact for F '26, F '27 and F '28. Is that what the market should be thinking going forward, please? I ask because it's the question I get asked the most.
各位早安,團隊,謝謝讓我提問。我可能是在重複問已經談過的問題,但我只是想把它講清楚,也請你們協助釐清:你們會把獲利再投資,使得 2026 財年、2027 財年與 2028 財年的影響接近於零。市場接下來應該用這樣的方式來思考嗎?我之所以問,是因為這是我被問到最多的問題。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah, that's that's fine. No horses flogged, David. Happy you asked the question. So, not -- we're not giving guidance beyond 2026, but it's a reasonable expectation that in 2026 -- in 2027 that we will be investing other than -- for risk management and for appropriate balance sheet management purposes, we'll be investing the majority of our earnings back into the company, okay? So that's in a number of different areas, that's in R&D.
是的,那樣可以。不用鞭打死馬了,David。很高興你提出這個問題。所以,我們不會提供 2026 年以後的指引,但合理的預期是,在 2026 年——到 2027 年,我們將會(除風險管理與適當的資產負債表管理目的之外)把我們的大部分盈餘再投資回公司,好嗎?所以這會在多個不同領域,包括研發(R&D)。
That's also in growing and developing our commercial team, and, of course, we continue to also invest in infrastructure and capital works to support the business. So it's not all just R&D, but a profit objective for this year and next year is not the name of the game.
也包括擴大並培養我們的商業團隊,當然,我們也會持續投資於基礎設施與資本工程以支援業務。所以不全然只是研發,但今年與明年的重點並不是追求獲利目標。
Operator
Operator
Thank you. Our next question comes from David Bailey --
謝謝。下一個問題來自 David Bailey——
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Do you have further comment, David, that you'd like to ask? All right. Well, we'll move on. This is a very challenging conferencing service, and I apologize to those that are participating. Would we -- can we move on to the next question, please?
David,你還有想補充提問的內容嗎?好。那我們繼續。這個電話會議服務非常具挑戰性,我向所有參與者致歉。我們——可以請進行下一個問題嗎?
Operator
Operator
David Bailey, Morgan Stanley.
David Bailey,Morgan Stanley。
David Bailey - Equity Analyst
David Bailey - Equity Analyst
Yeah. Thanks. Hi, everyone, it's a follow on from Dr. Stanton's question. Just from Darren, there was a clear comment there that I think that the investment in growth will consider commercial performance. I think that was interesting from our perspective.
是的。謝謝。各位好,我想延續 Stanton 博士的問題。就 Darren 的說法而言,他有一個很明確的評論:成長投資會考量商業表現。從我們的角度看,這點很有意思。
It's just as we look at these sales guidance for '26 and the R&D guidance for '26, should we think that if the commercial performance is of the upper and lower end of those ranges, the R&D will follow? And an extension of that within the R&D spend, is the earliest stage clinical trials, are they the ones that would potentially be put on hold for a little bit to the extent that commercial performance doesn't meet expectations?
我們在看 2026 年的銷售指引與 2026 年的研發指引時,是否應該理解為:如果商業表現落在那些區間的上緣或下緣,研發也會隨之調整?另外,在研發支出內部,最早期階段的臨床試驗是否會是那些在商業表現未達預期時,可能會先暫緩一段時間的項目?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Well, I can start Darren, and then maybe if you want to add anything. I mean, so yes, we've focused the -- we've chosen in this presentation to highlight the clinical studies that are the real priorities for the company, so that that's the five studies, including the BiPASS study. We are obviously going to be investing in other clinical studies this year and to the extent that we need to make adjustments. It'll be outside of that sort of ring-fenced five studies that this four Therapeutic studies and the BiPASS study.
嗯,我可以先回答,Darren,然後你若想補充也可以。我的意思是,是的,我們在這次簡報中選擇聚焦並強調公司真正優先的臨床研究,也就是那五項研究,包括 BiPASS 研究。顯然我們今年也會投資其他臨床研究,而若需要做調整,會是在那個「圈定」的五項研究之外——也就是四項治療性研究與 BiPASS 研究之外。
We clearly expect that 2026 is going to be a strong year. We don't expect to have any difficulties in financing our R&D pipeline, but as you have noted, and as Darren, I think, made it very clear, generally, we take the view that our R&D investment is discretionary and we can make adjustments as required.
我們明確預期 2026 年會是強勁的一年。我們不預期在為研發管線籌資方面會有任何困難,但如你所指出、也如 Darren 我想已說得很清楚,一般而言,我們的看法是研發投資具有裁量性,必要時可以做調整。
Darren, do you want to add anything? Okay. I'll take that as a no. Shall we move on to the next question, please?
Darren,你想補充什麼嗎?好。那我就當作不需要。我們進行下一個問題,請。
Darren Smith - Group Chief Financial Officer
Darren Smith - Group Chief Financial Officer
Craig Wong-Pan, RBC.
Craig Wong-Pan,RBC。
Craig Wong-Pan - Equity Analyst
Craig Wong-Pan - Equity Analyst
Hi there. Just a question on the 25% growth in Precision Medicine. I was wondering how much growth was coming from markets outside of the US?
你好。我想問一下 Precision Medicine 25% 的成長。我想知道有多少成長是來自美國以外的市場?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Sure. I'll answer that one, and then maybe Darren, if you want to chime in on anything that I've missed. Right now, because we only achieved our European reimbursements towards the back end of last year. It's a very small proportion of the revenue is currently ex-US, the majority of it is -- 95% of it is US based.
好的。我先回答這題,然後 Darren,如果你想補充我遺漏的部分也可以。目前因為我們是在去年年底才取得歐洲的給付(reimbursement),所以目前美國以外的營收占比非常小,絕大多數——95%——都來自美國。
We obviously expect that mix to change over the course of this year and also as we add in other markets such as Japan, which has a high-value PET -- advanced PET procedure code that's quite internationally competitive. But for the moment, for the most part, the majority of our revenue is US based. Shall we have the next question, please?
我們當然預期這個組合在今年期間會改變,並且隨著我們加入其他市場(例如日本)而改變;日本有一個高價值的 PET——先進 PET 檢查程序代碼,在國際上相當具競爭力。但就目前而言,我們的營收大多仍以美國為主。請下一個問題。
Operator
Operator
Andy Hsieh, William Blair.
Andy Hsieh,William Blair。
Andy Hsieh - Equity Analyst
Andy Hsieh - Equity Analyst
Yeah. Thanks for taking our question. Chris, I wanted to ask you about your (multiple speakers) Can you hear me?
是的。謝謝讓我們提問。Chris,我想問你關於你們的(多位講者)你聽得到我嗎?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yes, go, please.
是的,請說。
Andy Hsieh - Equity Analyst
Andy Hsieh - Equity Analyst
So Chris, I want to ask you about the recent collaboration with Atley and Stanford focusing on Astatine-211. So in your pipeline, you have three alpha-emitters, Actinium-225, you had lead generator that's in progress, and then, and now Acetane having a California supply chain.
Chris,我想問你們最近與 Atley 和 Stanford 的合作,聚焦在 Astatine-211。在你們的管線中,你們有三種 α 放射體:Actinium-225,你們有一個正在進行中的鉛(lead)發生器,然後現在 Astatine 也有加州的供應鏈。
So I'm curious about your view on this isotope, another short half-life. Just wondering about how it fits into your product portfolio.
所以我很好奇你對這個同位素(另一種短半衰期)的看法。想請教它如何融入你們的產品組合。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah. It's a bit of sort of outside of the major activity area, but essentially, we do see the value in alpha-emitters. The majority of our late stage programs, our [beta-emitting] isotopes. We think that they're going to be a work horse for the foreseeable future, but we can see alphas coming over the horizon.
是的。這有點算是在主要活動領域之外,但基本上,我們確實看見 α 放射體的價值。我們多數後期項目是使用[β 放射]同位素。我們認為在可預見的未來,它們會是主力,但我們也看到 α 的趨勢正在浮現。
As you note, most of our clinical stage programs are with Actinium. It's probably from a supply chain perspective, the lowest hanging fruit. We have one program, TLX102, which is with Astatine. That's in early clinical translation.
如你所說,我們大多數臨床階段項目是使用 Actinium。從供應鏈角度看,這可能是最容易取得的選項。我們有一個項目 TLX102 使用 Astatine。那正處於早期臨床轉譯階段。
We think that for applications where targeting agent needs to cross the blood-brain barrier that radio halogens are a better -- perhaps a more practical pathway than a radiometal with a chelator. So we are exploring Astatine mostly in the CNS setting. And then we do, as you note, have a lead generator that we've developed, it's a very novel and very compelling generator design that we think can be rolled out for large scale lead production.
我們認為,對於需要讓標靶分子穿越血腦屏障的應用,放射性鹵素(radio halogens)可能比帶有螯合劑的放射性金屬更好——或許更可行的路徑。因此我們主要在中樞神經系統(CNS)的情境中探索 Astatine。另外,如你所提,我們也開發了一個鉛發生器,這是一個非常新穎且很有吸引力的發生器設計,我們認為可用於大規模鉛的生產。
We currently today do not have any clinical programs using Lead-212, but we have a number of pre-clinical programs that we expect to take into patients by the end of this year that are not currently disclosed, and they have the potential to use Lead-212. We are exploring several different isotopes. But I think as a company, we've elected to put a proportion -- not a large proportion, but a modest proportion of our R&D expenditure into understanding the future landscape of Alpha because we think it has some potential. I hope that answers your question.
目前我們沒有任何使用 Lead-212 的臨床項目,但我們有多個臨床前項目,預期在今年年底前推進到病人試驗;這些目前尚未對外揭露,且有可能使用 Lead-212。我們正在探索幾種不同的同位素。但我想以公司角度,我們選擇把一部分——不是很大,但適度比例——的研發支出投入到理解 α 的未來版圖,因為我們認為它具有一些潛力。希望這回答了你的問題。
Andy Hsieh - Equity Analyst
Andy Hsieh - Equity Analyst
Yeah, certainly. Thanks you.
是的,當然。謝謝你。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
The next question, please.
下一個問題,請。
Operator
Operator
[David Dye], UBS.
[David Dye],UBS。
David Dye
David Dye
Great. Hey, thanks for taking my question. Just on the gross margin for business, it seems like it's remaining stable at 53%. But then there are less business gross margin has been quite poor. So just thinking about the gross margin for all as business moving forward, what are some of the key drivers of gross margin especially for the RLS business that you can provide?
很好。謝謝讓我提問。關於業務的毛利率,看起來維持在 53% 相當穩定。但 RLS 業務的毛利率一直相當差。所以在思考未來整體業務毛利率走勢時,你們能否分享一些毛利率的關鍵驅動因素,特別是針對 RLS 業務?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Well let's make a comment and then I'll invite Darren to chime in. So the RLS business --so just to be clear, when we report the RLS segment, we report the RLS segment purely in terms of third-party products. So these are not Telix products. These are, for the most part, fairly generic nuclear medicine products, and RLS is operating cost is largely covered by delivering those third-party products.
好,那我先做個評論,然後再請 Darren 補充。關於 RLS 業務——為了說清楚,當我們報告 RLS 分部時,我們是純粹以第三方產品的角度來報告 RLS 分部。所以這些不是 Telix 的產品。這些大多是相當通用的核醫產品,而 RLS 的營運成本主要是透過交付這些第三方產品來涵蓋。
So a way to -- a useful way to think about it is as a subsidized -- third-party subsidized manufacturing infrastructure. And we report the products that go through the RLS network that are Telix products, they are captured in the segmental reporting for Precision Medicine. So I just really want to make that very clear.
因此,一個——一個有用的理解方式是,把它視為一個由第三方補貼的製造基礎設施。而我們會把經由 RLS 網路流通、屬於 Telix 的產品,歸入精準醫療(Precision Medicine)的分部報告中。所以我只是想把這點講得非常清楚。
So when you say the gross margins for RLS are not very good, it's got nothing to do with Telix's product portfolio. RLS margins because these are generic, sort of fairly commoditized nuclear medicine products, they have a much, much lower margin. We provided an average margin last year, which I think freaked a lot of people out because all of a sudden we went from mid-60s margins down to mid-50s margins or low-50s margins. That was an average effect across all of the products in the group, including the RlS products. Does that make sense?
所以當你說 RLS 的毛利率不太好時,這與 Telix 的產品組合完全無關。RLS 的毛利率之所以較低,是因為這些是通用、相對商品化的核醫產品,毛利率要低得多、低得多。我們去年提供了一個平均毛利率,我想那讓很多人嚇了一跳,因為我們突然從 60% 中段的毛利率降到 50% 中段或 50% 初段。那是整個集團所有產品(包含 RLS 產品)加總後的平均效果。這樣說有道理嗎?
David Dye
David Dye
Yeah, that makes sense. Thanks.
有,這樣就說得通了。謝謝。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah. So, yeah, so don't be sidetracked by RLS. The most important thing is that when we put our products through RLS we -- that gross margin number, which we report faithfully for the Precision Medicine business as sort of mid-60%. That's our -- that above the line cost is our distributor margin, which clearly is different when we run a product through our own pharmacy network.
好。所以,對,別被 RLS 分散注意力。最重要的是,當我們把自家產品透過 RLS 來配送時——我們在精準醫療業務中如實揭露的那個毛利率數字,大約是 60% 中段。那是我們——線上成本(above the line cost)是我們的經銷商毛利,這在產品透過我們自有藥局網路運作時顯然會不同。
Now it's critically important for us to maintain key distribution partnerships in key markets. So we obviously do pay that above the line cost, but when we produce a product that goes through our nuclear pharmacy network, the gross margin is rather different. So you should expect to see, as we have a larger share of our product volume going through our in-house pharmacy network, that that gross margin number has the potential to improve the trend towards 70%.
現在,對我們而言,在關鍵市場維持重要的配送合作夥伴關係至關重要。所以我們當然會支付那個線上成本,但當我們生產的產品是透過我們的核藥局網路配送時,毛利率就會相當不同。因此你應該可以預期,隨著更多產品量改由我們內部藥局網路配送,那個毛利率數字有機會改善,趨勢朝 70% 靠攏。
Operator
Operator
Andrew Paine, CLSA.
Andrew Paine,CLSA。
Andrew Paine - Equity Analyst
Andrew Paine - Equity Analyst
Thanks for taking my question. This may be one for Kevin, but you mentioned winning in the PSMA is about executing it at scale, and we've seen that in the growth and the challenges you've overcome in that market so far. You spent a bit of time talking about this, but how clear is it that mote there for you given the potential competition on the horizon? And also, can you just dig into the changes in camera technology and how you feel as supportive to the sensitivity of PSMA imaging, which may not be fully appreciated?
謝謝讓我提問。這題可能要問 Kevin,但你提到在 PSMA 領域取勝關鍵在於能以規模化執行,而我們也在你們至今在該市場的成長與克服的挑戰中看到了這點。你花了一些時間談這個,但考量到地平線上可能出現的競爭,你們在那裡的護城河有多明確?另外,你能否再深入談談相機技術的變化,以及你如何看待它對 PSMA 影像敏感度的支持(這點可能尚未被充分理解)?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Well, I think Kevin's done a great job of running through what the competitive barriers to entry, and they're multiple. I mean, it's not just product, it's also clinical, it's also manufacturing and supply chains. So I'm not sure what competitor you're talking about that's coming immediately on the horizon, but nonetheless, we see those as, I mean, pretty well enumerated sort of barriers to entry for competition.
嗯,我認為 Kevin 已經把競爭者進入門檻講得很清楚,而且門檻是多重的。也就是說,不只是產品,還包括臨床、製造以及供應鏈。所以我不確定你指的是哪個競爭者會在近期立刻出現,但無論如何,我們認為這些都是——我想——相當清楚列舉出的競爭進入障礙。
On the topic of camera technology, generally speaking, we've seen a step change in sensitivity on PET cameras over the last three to five years, because of the demand for PET imaging, not just in prostate cancer but across a whole lot of indications including neuro oncology, neurodegeneration, cardiovascular disease. We're seeing a lot of camera installation going in. And the next generation of scanners are an order of magnitude more sensitive.
關於相機技術這個主題,一般而言,過去三到五年我們看到 PET 相機的敏感度出現了躍升式的提升,原因是 PET 影像的需求增加,不僅在前列腺癌,也涵蓋許多適應症,包括神經腫瘤、神經退化以及心血管疾病。我們看到大量相機裝機正在進行。而下一代掃描儀的敏感度高出一個數量級。
And so that just means that we have to keep abreast of it. We need to make sure that we're running clinical trials and clinical studies that demonstrate the improved utility. We are clearly detecting disease earlier and earlier. I mean, we have -- in our most recent studies that were done in China, for example, with absolutely state-of-the-art scanners because they're brand new scanners. We're seeing PSA levels down to fractions of a nanogram per mil.
因此這代表我們必須持續跟上。我們需要確保進行臨床試驗與臨床研究,以證明其效用提升。我們顯然能更早、也更早地偵測到疾病。我的意思是,我們——例如在中國完成的最新研究中,使用的是絕對最先進的掃描儀,因為那些都是全新的設備。我們看到 PSA 水平低到每毫升不到一奈克的零點幾。
And so, the camera technology is part of the complimentary story to trace your development that should not be forgotten about. I think I'll pause there in terms of that particular topic. There isn't too much more else to say. Is there, another question?
因此,相機技術是你們示蹤劑(tracer)發展故事中相輔相成的一部分,不應被忽略。我想在這個特定主題上先停在這裡。沒有太多其他可以補充的。還有其他問題嗎?
Operator
Operator
Melissa Benson, Barrenjoey. Your line is open.
Melissa Benson,Barrenjoey。你的線路已開通。
Melissa Benson - Analyst
Melissa Benson - Analyst
Thanks for taking my question. So Kevin mentioned you had a full alignment on the agreed deliverables with the FDA for the (multiple speakers)
謝謝讓我提問。所以 Kevin 提到你們已就與 FDA 約定的交付項目達成完全一致,針對(多位講者)
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Melissa, I'm sorry. Yeah, I can't hear -- now I can hear you. Go on.
Melissa,不好意思。對,我聽不到——現在聽到了。請繼續。
Melissa Benson - Analyst
Melissa Benson - Analyst
Oh, I'm sorry. So I think Kevin was mentioning there was a alignment on the agreed deliverables with FDA for the [cakes]. So I was just wondering if there's anything you can share regarding what those agreed deliverables are. But specifically if there's any new clinical data required, or if it's more pre-clinical analytical data only?
喔,不好意思。所以我想 Kevin 剛才提到,針對[cakes],你們已就與 FDA 約定的交付項目達成一致。所以我想請問,你們是否能分享那些約定的交付項目是什麼。尤其是是否需要任何新的臨床數據,還是只需要更多臨床前的分析數據?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah. Most of the CMC remediation topics are around laboratory documentation, manufacturing documentation and process documentation. We do have a deliverable to the FDA around a comparability between the research grade material that we used in the Phase 3 trial and the commercial scale-up material. But we have that data set well in hand, and it's not a material time delay to the resubmission.
對。大多數 CMC 補正(remediation)議題都圍繞在實驗室文件、製造文件以及製程文件。我們確實有一項要交付給 FDA 的內容,是關於我們在第三期試驗中使用的研究級材料與商業化放大生產材料之間的可比性(comparability)。但那套數據我們已經掌握得很完整,對重新遞交並不會造成實質的時間延遲。
Operator
Operator
Steve Wheen, Jordan.
Steve Wheen,Jordan。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Is there another question?
還有其他問題嗎?
Steve Wheen - Analyst
Steve Wheen - Analyst
Yeah, good morning. Chris, can you hear me? Hello?
有,早安。Chris,你聽得到我嗎?哈囉?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
I guess we've lost that one. Anybody else?
看來我們失去那條線了。還有其他人嗎?
Steve Wheen - Analyst
Steve Wheen - Analyst
Chris, are you there?
Chris,你在嗎?
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yes, I'm here.
是的,我在。
Steve Wheen - Analyst
Steve Wheen - Analyst
Yeah, okay. It's Steve here. So my question was just a bit of an extension of some of the others. But I guess for Kevin, I'm just trying to understand the European market with regards to Illuccix and Gozellix. I guess, just they've been approved for some time. The launch in the US obviously was incredibly rapid and just trying to understand what's holding it back or slowing it to not really be much of a feature for your growth in the next 12 months.
好,好的。我是 Steve。所以我的問題算是延伸前面幾個問題。但我想問 Kevin,我試著理解歐洲市場對 Illuccix 和 Gozellix 的情況。我想,它們已經核准一段時間了。在美國的上市顯然非常迅速,我只是想了解是什麼在拖住或放慢進度,使其在未來 12 個月並未真正成為你們成長的一個重要亮點。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Kevin, I can start and then maybe you can finish. I mean, it's not that it's not a feature, it's just that the European market has a very different reimbursement landscape. The US has a much more immediacy between product approval and reimbursement, whereas in Europe sometimes there can be as long as 9 or 12 months delay between product approval and reimbursement, and there's simply no material product sales until you have reimbursement.
Kevin,我可以先說,然後你再補充。我的意思是,並不是它不是一個亮點,只是歐洲市場的給付(reimbursement)環境非常不同。美國在產品核准與給付之間的銜接更即時;但在歐洲,有時產品核准與給付之間可能會有長達 9 到 12 個月的延遲,而且在取得給付之前,基本上不會有任何具實質性的產品銷售。
It's also not a class reimbursement, it's an individual product reimbursement in most countries. And so until you have reimbursement, you simply don't have material sales. So for the what you would classify as the traditional EU5 countries, we have only just received reimbursement in some of them.
此外,在多數國家這也不是類別給付(class reimbursement),而是單一產品給付(individual product reimbursement)。因此,在取得給付之前,你基本上不會有實質銷售。所以就你會歸類為傳統 EU5 國家的部分,我們也才剛在其中一些國家取得給付。
Kevin, I don't know if you want to add anything there.
Kevin,我不知道你是否想補充什麼。
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Kevin Richardson - Chief Executive Officer - Telix Precision Medicine
Yeah, there's very little other color to add than my prepared remarks, which was really 2025, the international team under that direction was really focused on gaining market access through reimbursement. And now we -- in that EU5, the plans now are to execute those market launches. And so you will see that as we continue to grow in 2026, as we execute against that launch.
是的,除了我事先準備的發言之外,幾乎沒有太多可以補充的內容;也就是說,2025 年在那個方向之下,國際團隊確實是聚焦於透過給付來取得市場准入。而現在——在 EU5,那些計畫就是要去執行市場上市。因此,當我們在 2026 年持續成長、並推進該上市執行時,你就會看到這一點。
But Chris is right, each country is different, each product is different. So it takes a bit to get that approved in the system and then begin the launch. So we're in the midst of that right now.
但 Chris 說得沒錯,每個國家都不同、每個產品也不同。所以要在體系內取得核准,然後開始上市,確實需要一些時間。所以我們現在正處於這個過程中。
Steve Wheen - Analyst
Steve Wheen - Analyst
Right. Okay. That's clear. Can I just ask an unrelated question just with regards to your R&D? The expensing of the cakes through the R&D line. Is there a shelf life for that particular inventory? Just with regards to -- just noticed your comment that there is the potential once it's approved by the FDA that that could then come back and be backed out of the P&L.
好的。好。這很清楚。我可以再問一個不相關的問題,關於你們的研發嗎?把那些蛋糕(cakes)的費用列在研發費用線下認列。那一批特定存貨有保存期限嗎?我注意到你提到,一旦獲得 FDA 核准,這些費用可能就能回沖、並從損益表中扣回。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah, that's right. That's our expectation and the shelf life goes far beyond the launch time of the product.
是的,沒錯。這是我們的預期,而且其保存期限遠遠超過產品上市的時間。
Operator
Operator
Shane Storey, Cannacord Genuity.
Shane Storey,Cannacord Genuity。
Shane Storey - Analyst
Shane Storey - Analyst
Sorry for extending the time, everyone. My question was going to come off the back of Melissa's question actually on Zircaix, except everything you've just said there. But just as far as how we should think about FDA's review phase once the resubmitted BLA is accepted. We've been sort of assuming six months. We're just unsure how the breakthrough status and priority review might influence that, if at all.
抱歉各位,我延長了一點時間。我的問題其實是接著 Melissa 關於 Zircaix 的問題來問的,不過你們剛剛已經把那部分都說到了。但我想問的是,一旦重新提交的 BLA 被受理後,我們應該如何看待 FDA 的審查階段?我們一直大致假設是六個月。只是我們不確定突破性療法資格(breakthrough status)與優先審查(priority review)是否、以及在多大程度上會影響這個時程。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah, we don't know yet for Zircaix. For Pixclara, we have a reasonable idea that it's going to be a rapid review also because it's a single-issued [CRL]. We could imagine for the Zarcaix review because there are a number of issues that it may take longer, but we haven't received guidance yet from the FDA on this topic. We will be engaging with the agency shortly on this topic as we are preparing to resubmit. But we won't know that information for a little bit when it comes to Zarcaix.
是的,針對 Zircaix 我們目前還不知道。至於 Pixclara,我們相當有把握它也會是快速審查,因為它是單一議題的 [CRL]。我們可以想像 Zarcaix 的審查,因為有多個議題,可能會花更久,但我們尚未就此主題收到 FDA 的指引。在我們準備重新提交時,會很快就這個主題與主管機關進一步溝通。但就 Zarcaix 而言,我們還需要一段時間才會知道這些資訊。
Shane Storey - Analyst
Shane Storey - Analyst
Thanks, Chris.
謝謝你,Chris。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah, no worries. I do know that it has a breakthrough designation, and I actually want to compliment the agency. They've been highly engaged, very helpful, very proactive. They give us a lot of extra time around the type A meeting that they really didn't need to do. So we feel like it's a pretty good collaboration. And we're working with the agency towards the drug approval and nothing less than that.
好的,不客氣。我確實知道它有突破性療法認定(breakthrough designation),而且我其實想稱讚一下主管機關。他們投入度很高、非常有幫助,也很積極主動。他們在 A 類會議(type A meeting)方面給了我們很多額外時間,其實他們不必這麼做。所以我們覺得這是一個相當不錯的合作。我們也正與主管機關一起朝藥品核准的目標努力,沒有其他更低的目標。
Okay, I think, I have a feeling that we're wrapping it up there. I don't know if there's any more questions coming through.
好的,我想我有種感覺,我們差不多要在這裡收尾了。我不確定是否還有其他問題進來。
Operator
Operator
David Stanton, Jefferies.
David Stanton,Jefferies。
David Stanton - Analyst
David Stanton - Analyst
Chris, I note that you've talked to Part Two interim analysis in calendar '26. I wonder if you could sort of give us any kind of timeline as to when that might be? Is it third quarter or is it fourth quarter? What should we be thinking there? Thank you.
Chris,我注意到你提到第二部分(Part Two)的期中分析會在 2026 年曆年進行。我想請你能否給我們一個大概的時間點?會是在第三季還是第四季?我們應該怎麼看待這個時程?謝謝。
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Christian Behrenbruch - Group Chief Executive Officer, Managing Director, Executive Director
Yeah. Obviously, I get increasingly reluctant to estimate timelines on clinical trials because we (technical difficulty) by like to the day or to the week rather than to the quarter. But right now, the Part Two study is recruiting really nicely. We're seeing good site expansion on getting plenty of patients consented into the study.
是的。顯然,我對臨床試驗時程的估計會越來越保守,因為我們(技術問題)更傾向於精確到某一天或某一週,而不是精確到某一季。但目前第二部分研究的收案進展非常順利。我們看到站點擴增的情況良好,也有足夠多的病患同意加入研究。
That interim analysis is based on about 80 or 90 events, I don't know the exact number, some time -- somewhere around that. And we would expect that that should lead based on the current recruitment trajectory for some time in Q4 of this year for that futility analysis to read out. So that's the reason why we have it there in the calendar for this year.
那個期中分析是以大約 80 或 90 個事件為基礎,我不確定確切數字,大概是在那個範圍。依照目前的收案軌跡,我們預期今年第四季的某個時間點,該無效性(futility)分析會有結果讀出。所以這就是我們把它放在今年年曆上的原因。
Okay, well, I think that was the last question. I just want to apologize profusely to all the attendees for the audio challenges we've had today. It's the new conference provider. I'm not sure we'll be using it again in the future.
好的,那我想這就是最後一個問題了。我想就我們今天遇到的音訊問題,向所有與會者致上最深的歉意。這是新的會議服務供應商。我不確定未來我們是否還會再使用它。
But I just wanted to thank you for your questions and for your attention. And obviously, if there are follow-up questions, we'll be happy to receive them directly and follow-up in due course. Thank you for your time today.
不過我還是想感謝各位的提問與關注。當然,如果有後續問題,我們也很樂意直接收到,並在適當時候跟進回覆。感謝各位今天撥冗參與。
Operator
Operator
This concludes today's conference call. Thank you for participating. You may now disconnect.
今天的電話會議到此結束。感謝各位參與。您現在可以掛線。